Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kumar V Penmetsa"'
Autor:
Heather L Gardner, Sarah B Rippy, Misty D Bear, Kim L Cronin, Heather Heeb, Holly Burr, Claire M Cannon, Kumar V Penmetsa, Srikant Viswanadha, Swaroop Vakkalanka, Cheryl A London
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195357 (2018)
RV1001 is a novel, potent, and selective PI3Kδ inhibitor. The purpose of this study was to evaluate the safety and efficacy of RV1001 in canine Non-Hodgkin lymphoma (NHL).Inhibition of endogenous pAKT by RV1001 in primary canine NHL cells was determ
Externí odkaz:
https://doaj.org/article/2cde8c7101d8458aaeb72cfb3d0632c4
Autor:
Zui Pan, Srikant Viswanadha, Sangyong Choi, Liwu Fu, Yan Chang, Xiaoli Zhang, Kumar V. Penmetsa, Henry Tran, Chaochu Cui
Publikováno v:
Cancer Letters. 432:169-179
Esophageal cancer (EC) is the 6th leading cause of cancer mortality worldwide with poor prognosis, hence more effective chemotherapeutic drugs for this deadly disease are urgently needed. We previously reported that high expression of Orai1, a store-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a6440793967e43bb2b78949d3910e4
https://doi.org/10.1016/j.canlet.2018.06.006
https://doi.org/10.1016/j.canlet.2018.06.006
Autor:
Philip A. Philip, Amro Aboukameel, Srikant Visvanadha, Kumar V. Penmetsa, Rachel E. Sexton, Ramzi M. Mohammad, Gabriel Mpilla, Asfar S. Azmi, Mohammad Najeeb Al-Hallak
Publikováno v:
Cancer Research. 80:234-234
Background: Dihydroorotate dehydrogenase (DHODH) is an enzyme which is critically involved in process of de novo pyrimidine biosynthesis. Therefore, it plays important roles in cell proliferation, mitosis and cellular metabolism. Importantly, overexp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9661935e0d853cc43a1d6cbd8ce70b1
https://doi.org/10.1158/1538-7445.am2020-234
https://doi.org/10.1158/1538-7445.am2020-234
Autor:
Mark Szlaczky, Maria Diab, Mohammed Najeeb Al-Hallak, Gabriel Mpilla, Srikant Viswanadha, Amro Aboukameel, Asfar S. Azmi, Steve Kim, Anteneh Tesfaye, Mandana Kamgar, Rachel E. Sexton, Philip A. Philip, Kumar V. Penmetsa, Husain Yar Khan, Ramzi M. Mohammad
Publikováno v:
Cancers, Vol 12, Iss 3, p 750 (2020)
Cancers
Volume 12
Issue 3
Cancers
Volume 12
Issue 3
Pancreatic ductal adenocarcinoma (PDAC) remains an unmet clinical problem in urgent need of newer molecularly driven treatment modalities. Calcium signals, particularly those associated with calcium release-activated calcium (CRAC) channels, are know
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff6ef61df351213cd62d7d7fad6a632
https://doi.org/10.3390/cancers12030750
https://doi.org/10.3390/cancers12030750
Publikováno v:
Molecular Cancer Therapeutics. 18:C045-C045
Background: Store-operated calcium entry (SOCE) through calcium release activated calcium (CRAC) channels contribute to calcium influx in non-excitable cells. Elevation of cytosolic calcium through SOCE mediates an array of cellular responses includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d85ea73667fcfb8079acdce5d0cfce60
https://doi.org/10.1158/1535-7163.targ-19-c045
https://doi.org/10.1158/1535-7163.targ-19-c045
Publikováno v:
Molecular Cancer Therapeutics. 18:C044-C044
Background: Interventions that promote differentiation of immature blasts have been shown to be a promising therapeutic strategy for the treatment of AML. Inhibition of dihydroorotate dehydrogenase (DHODH), a rate limiting enzyme in pyrimidine synthe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21a19fed5848e861634febfab796615a
https://doi.org/10.1158/1535-7163.targ-19-c044
https://doi.org/10.1158/1535-7163.targ-19-c044
Autor:
Yan Chang, Chaochu Cui, Srikant Viswanadha, Xiaoli Zhang, Zui Pan, Kumar V. Penmetsa, Liwu Fu
Publikováno v:
The FASEB Journal. 32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a87dd7bdc636a57aebf3cec2d36fa71
https://doi.org/10.1096/fasebj.2018.32.1_supplement.750.38
https://doi.org/10.1096/fasebj.2018.32.1_supplement.750.38
Autor:
Shelley Orwick, Larry Beaver, Bridget Carmichael, Kumar V. Penmetsa, Erin Hertlein, John C. Byrd, Srikant Viswanadha, Jean Truxall, Ola A. Elgamal, Amy Lehman
Publikováno v:
Cancer Research. 78:1938-1938
Acute myeloid leukemia (AML) is the most prevalent adult leukemia characterized by genetic or mutational disruption of myeloid differentiation, growth arrest, and apoptosis. Standard “7 + 3” chemotherapy consisting of cytarabine in combination wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e133aeb2ebff0bfb3020c10fa6294b4
https://doi.org/10.1158/1538-7445.am2018-1938
https://doi.org/10.1158/1538-7445.am2018-1938
Publikováno v:
Cancer Research. 78:1889-1889
Background: Multiple Myeloma (MM) accounts for approximately 2.1% of all cancer deaths with a 5-year median survival rate of 49.6%. Besides chemotherapy, treatment options include monoclonal antibodies, immunomodulatory agents, and proteasome inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0fa59d1b3665b3574ac10cf814c6080
https://doi.org/10.1158/1538-7445.am2018-1889
https://doi.org/10.1158/1538-7445.am2018-1889
Autor:
Sarah B. Rippy, Claire M Cannon, Srikant Viswanadha, Kim L. Cronin, Heather L. Gardner, Cheryl A. London, Swaroop Vakkalanka, Kumar V. Penmetsa, Holly Burr, Heather Heeb, Misty D. Bear
Publikováno v:
PLoS ONE, Vol 13, Iss 4, p e0195357 (2018)
PLoS ONE
PLoS ONE
Background RV1001 is a novel, potent, and selective PI3Kδ inhibitor. The purpose of this study was to evaluate the safety and efficacy of RV1001 in canine Non-Hodgkin lymphoma (NHL). Methods and results Inhibition of endogenous pAKT by RV1001 in pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f58646b077efe12ad6c929e1d20a547f
https://doi.org/10.1371/journal.pone.0195357
https://doi.org/10.1371/journal.pone.0195357